Cargando…

Type of atrial fibrillation and outcomes in patients without oral anticoagulants

BACKGROUND: The effect of type of atrial fibrillation (AF) on adverse outcomes in Chinese patients without oral anticoagulants (OAC) was controversial. HYPOTHESIS: The type of AF associated with adverse outcomes in Chinese patients without OAC. METHODS: A total of 1358 AF patients without OAC from a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Jiameng, Yang, Yanmin, Zhu, Jun, Wu, Shuang, Wang, Juan, Zhang, Han, Shao, Xinghui, Lyu, Siqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852164/
https://www.ncbi.nlm.nih.gov/pubmed/33314221
http://dx.doi.org/10.1002/clc.23519
_version_ 1783645766170968064
author Ren, Jiameng
Yang, Yanmin
Zhu, Jun
Wu, Shuang
Wang, Juan
Zhang, Han
Shao, Xinghui
Lyu, Siqi
author_facet Ren, Jiameng
Yang, Yanmin
Zhu, Jun
Wu, Shuang
Wang, Juan
Zhang, Han
Shao, Xinghui
Lyu, Siqi
author_sort Ren, Jiameng
collection PubMed
description BACKGROUND: The effect of type of atrial fibrillation (AF) on adverse outcomes in Chinese patients without oral anticoagulants (OAC) was controversial. HYPOTHESIS: The type of AF associated with adverse outcomes in Chinese patients without OAC. METHODS: A total of 1358 AF patients without OAC from a multicenter, prospective, observational study was included for analysis. Univariable and multivariable Cox regression models were utilized. Net reclassification improvement analysis was performed for the assessment of risk prediction models. RESULTS: There were 896(66%) patients enrolled with non‐paroxysmal AF (NPAF) and 462(34%) with paroxysmal AF (PAF). The median age was 70.9 ± 12.6 years, and 682 patients (50.2%) were female. During 1 year of follow‐up, 215(16.4%) patients died, and 107 (8.1%) patients experienced thromboembolic events. Compared with the PAF group, NPAF group had a notably higher incidence of all‐cause mortality (20.2% vs. 9.4%, p < .001), thromboembolism (10.5% vs. 3.8%, p < .001). After multivariable adjustment, NPAF was a strong predictor of thromboembolism (HR 2.594, 95%CI 1.534–4.386; p < .001), all‐cause death (HR 1.648, 95%CI 1.153–2.355; p = .006). Net reclassification improvement analysis indicated that the addition of NPAF to the CHA(2)DS(2)‐VASc score allowed an improvement of 0.37 in risk prediction for thromboembolic events (95% CI 0.21–0.53; p < .001). CONCLUSIONS: In Chinese AF patients who were not on OAC, NPAF was an independent predictor of thromboembolism and mortality. The addition of NPAF to the CHA(2)DS(2)‐VASc score allowed an improvement in the accuracy of the prediction of thromboembolic events.
format Online
Article
Text
id pubmed-7852164
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wiley Periodicals, Inc.
record_format MEDLINE/PubMed
spelling pubmed-78521642021-02-05 Type of atrial fibrillation and outcomes in patients without oral anticoagulants Ren, Jiameng Yang, Yanmin Zhu, Jun Wu, Shuang Wang, Juan Zhang, Han Shao, Xinghui Lyu, Siqi Clin Cardiol Clinical Investigations BACKGROUND: The effect of type of atrial fibrillation (AF) on adverse outcomes in Chinese patients without oral anticoagulants (OAC) was controversial. HYPOTHESIS: The type of AF associated with adverse outcomes in Chinese patients without OAC. METHODS: A total of 1358 AF patients without OAC from a multicenter, prospective, observational study was included for analysis. Univariable and multivariable Cox regression models were utilized. Net reclassification improvement analysis was performed for the assessment of risk prediction models. RESULTS: There were 896(66%) patients enrolled with non‐paroxysmal AF (NPAF) and 462(34%) with paroxysmal AF (PAF). The median age was 70.9 ± 12.6 years, and 682 patients (50.2%) were female. During 1 year of follow‐up, 215(16.4%) patients died, and 107 (8.1%) patients experienced thromboembolic events. Compared with the PAF group, NPAF group had a notably higher incidence of all‐cause mortality (20.2% vs. 9.4%, p < .001), thromboembolism (10.5% vs. 3.8%, p < .001). After multivariable adjustment, NPAF was a strong predictor of thromboembolism (HR 2.594, 95%CI 1.534–4.386; p < .001), all‐cause death (HR 1.648, 95%CI 1.153–2.355; p = .006). Net reclassification improvement analysis indicated that the addition of NPAF to the CHA(2)DS(2)‐VASc score allowed an improvement of 0.37 in risk prediction for thromboembolic events (95% CI 0.21–0.53; p < .001). CONCLUSIONS: In Chinese AF patients who were not on OAC, NPAF was an independent predictor of thromboembolism and mortality. The addition of NPAF to the CHA(2)DS(2)‐VASc score allowed an improvement in the accuracy of the prediction of thromboembolic events. Wiley Periodicals, Inc. 2020-12-12 /pmc/articles/PMC7852164/ /pubmed/33314221 http://dx.doi.org/10.1002/clc.23519 Text en © 2020 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Investigations
Ren, Jiameng
Yang, Yanmin
Zhu, Jun
Wu, Shuang
Wang, Juan
Zhang, Han
Shao, Xinghui
Lyu, Siqi
Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title_full Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title_fullStr Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title_full_unstemmed Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title_short Type of atrial fibrillation and outcomes in patients without oral anticoagulants
title_sort type of atrial fibrillation and outcomes in patients without oral anticoagulants
topic Clinical Investigations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852164/
https://www.ncbi.nlm.nih.gov/pubmed/33314221
http://dx.doi.org/10.1002/clc.23519
work_keys_str_mv AT renjiameng typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT yangyanmin typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT zhujun typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT wushuang typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT wangjuan typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT zhanghan typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT shaoxinghui typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants
AT lyusiqi typeofatrialfibrillationandoutcomesinpatientswithoutoralanticoagulants